Biotech Industry Examiner

Menu
Menu
subscribe now
Search
Novo Holdings Leads $100 Million Series C Financing for Asceneuron

Novo Holdings Leads $100 Million Series C Financing for Asceneuron

Novo Holdings has led a $100 million Series C financing

German Biotech CatalYm Raises $150 Million for Phase 2b Cancer Studies

German Biotech CatalYm Raises $150 Million for Phase 2b Cancer Studies

CatalYm, a German biotech company specializing in cancer immunotherapy, has

A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads

A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads

From Collapse to Comeback: Inside Biotech’s ‘Death-to-Rebirth’ Cycle

From Collapse to Comeback: Inside Biotech’s ‘Death-to-Rebirth’ Cycle

Syngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-Up

Syngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-Up

Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide

Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide

Breaking the Bias: How Precision Medicine Can Overcome Ancestral Disparities

Breaking the Bias: How Precision Medicine Can Overcome Ancestral Disparities

MOST POPULAR

News

AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal
Metsera’s Weight-Loss Drug MET-097i Shows Strong Clinical Results
Light-Based Microcapillary Monitoring Expands Precision in Biotechnology
Novo Holdings Leads $100 Million Series C Financing for Asceneuron

Funding

Aging Science

Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show
New Study Highlights the Impact of Early-Life Tobacco Exposure on Accelerated Aging

Genomics

M&A & Partnerships

Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
Merck KGaA in Talks to Acquire U.S. Biotech Firm SpringWorks, Valued at $4 Billion
Pharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 Billion
Orna Therapeutics Acquires ReNAgade Therapeutics to Enhance RNA Medicine Development

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top